Clene Inc. (CLNN)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
CLNN Insider Trading Activity
CLNN Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $583,390 | 3 | 33 |
Sells | $34,608 | 6 | 67 |
Related Transactions
| MATLIN DAVID J | director | 1 | $438,458 | 0 | $0 | $438,458 |
| Mortenson Mark | Chief Science Officer | 1 | $97,432 | 0 | $0 | $97,432 |
| Etherington Robert Dee | Chief Executive Officer | 1 | $47,500 | 0 | $0 | $47,500 |
| General Resonance LLC | 10 percent owner | 0 | $0 | 6 | $34,608 | $-34,608 |
About Clene Inc.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Insider Activity of Clene Inc.
Over the last 12 months, insiders at Clene Inc. have bought $583,390 and sold $34,608 worth of Clene Inc. stock.
On average, over the past 5 years, insiders at Clene Inc. have bought $6.12M and sold $535,013 worth of stock each year.
Highest buying activity among insiders over the last 12 months: MATLIN DAVID J (director) — $438,458. Mortenson Mark (Chief Science Officer) — $97,432. Etherington Robert Dee (Chief Executive Officer) — $47,500.
The last purchase of 92,307 shares for transaction amount of $438,458 was made by MATLIN DAVID J (director) on 2024‑09‑30.
List of Insider Buy and Sell Transactions, Clene Inc.
| 2025-03-19 | Sale | General Resonance LLC | 10 percent owner | 1,400 0.0172% | $4.40 | $6,160 | -6.50% | |
| 2025-03-18 | Sale | General Resonance LLC | 10 percent owner | 1,333 0.016% | $4.45 | $5,932 | -10.58% | |
| 2024-09-30 | MATLIN DAVID J | director | 92,307 1.4829% | $4.75 | $438,458 | +3.32% | ||
| 2024-09-30 | Etherington Robert Dee | Chief Executive Officer | 10,000 0.1606% | $4.75 | $47,500 | +3.32% | ||
| 2024-09-30 | Mortenson Mark | Chief Science Officer | 20,512 0.3295% | $4.75 | $97,432 | +3.32% | ||
| 2024-05-01 | Sale | General Resonance LLC | 10 percent owner | 13,000 0.0092% | $0.40 | $5,148 | -42.33% | |
| 2024-04-30 | Sale | General Resonance LLC | 10 percent owner | 13,000 0.0098% | $0.42 | $5,416 | -41.44% | |
| 2024-04-24 | Sale | General Resonance LLC | 10 percent owner | 10,000 0.0076% | $0.33 | $3,278 | -24.63% | |
| 2024-04-09 | Sale | General Resonance LLC | 10 percent owner | 22,500 0.0172% | $0.39 | $8,675 | -33.99% | |
| 2023-11-10 | MATLIN DAVID J | director | 250,002 0.1815% | $0.41 | $102,501 | -21.11% | ||
| 2023-06-26 | Stevens John Henry | director | 316,455 0.4161% | $0.80 | $253,164 | -45.16% | ||
| 2023-06-26 | Etherington Robert Dee | Chief Executive Officer | 25,000 0.0333% | $0.81 | $20,250 | -45.16% | ||
| 2023-06-16 | Ugwumba Chidozie | 10 percent owner | 7.5M 9.259% | $0.80 | $6M | -47.83% | ||
| 2023-06-16 | MATLIN DAVID J | director | 1.5M 1.8518% | $0.80 | $1.2M | -47.83% | ||
| 2023-06-16 | Mosca Alison | director | 2.39M 2.9559% | $0.80 | $1.92M | -47.83% | ||
| 2023-06-16 | Gay Jonathon | director | 105,625 0.1304% | $0.80 | $84,500 | -47.83% | ||
| 2022-11-02 | Ugwumba Chidozie | director | 990,099 1.4746% | $1.01 | $1,000,000 | -7.69% | ||
| 2022-11-02 | MATLIN DAVID J | director | 2.87M 4.2765% | $1.01 | $2.9M | -7.69% | ||
| 2022-11-02 | Gay Jonathon | director | 990,099 1.4746% | $1.01 | $1,000,000 | -7.69% | ||
| 2022-11-02 | Mosca Alison | director | 792,079 1.1797% | $1.01 | $800,000 | -7.69% |
Insider Historical Profitability
| General Resonance LLC | 10 percent owner | 710852 8.5379% | $2.46M | 0 | 9 | |
| MATLIN DAVID J | director | 444491 5.3387% | $1.54M | 22 | 0 | <0.0001% |
| Etherington Robert Dee | Chief Executive Officer | 40149 0.4822% | $138,915.54 | 2 | 1 | <0.0001% |
| Mortenson Mark | Chief Science Officer | 28949 0.3477% | $100,163.54 | 1 | 1 | |
| Ugwumba Chidozie | 10 percent owner | 13018908 156.3675% | $45.05M | 2 | 0 | <0.0001% |
| Mosca Alison | director | 3238375 38.8955% | $11.2M | 4 | 0 | <0.0001% |
| Stevens John Henry | director | 800204 9.6111% | $2.77M | 3 | 0 | <0.0001% |
| Gay Jonathon | director | 105625 1.2686% | $365,462.50 | 3 | 0 | <0.0001% |
| Glanzman Robert | Chief Medical Officer | 10564 0.1269% | $36,551.44 | 0 | 1 |
Historical Insider Profitability vs. Competitors
$14,315,062 | 61 | -6.21% | $31.49M | |
$53,490,060 | 55 | 19.35% | $31.76M | |
Clene Inc. (CLNN) | $23,895,365 | 34 | -37.28% | $28.81M |
$94,084,626 | 29 | -21.08% | $30.58M | |
$1,295,471 | 17 | 21.79% | $26.63M | |
$17,594,514 | 16 | -20.37% | $33.96M | |
$139,007,129 | 16 | 47.16% | $31.71M | |
$39,336,371 | 14 | -17.87% | $27.45M | |
$819,754 | 12 | -25.19% | $34M | |
$38,613,178 | 10 | 5.24% | $24.77M | |
$20,715,938 | 10 | -42.51% | $26.47M | |
$5,574,954 | 8 | -0.97% | $30.58M | |
$31,401,303 | 6 | -34.20% | $22.64M | |
$40,324 | 6 | 31.81% | $22.58M | |
$1,446,995 | 5 | -3.01% | $34.57M | |
$82,917 | 4 | -11.54% | $31.95M | |
$1,184,658 | 4 | -22.17% | $25.13M | |
$5,030,159 | 2 | -23.30% | $27.64M | |
$500,000 | 1 | -22.94% | $25.07M |
CLNN Institutional Investors: Active Positions
| Increased Positions | 13 | +50% | 161,968 | +15.95% |
| Decreased Positions | 9 | -34.62% | 688,390 | -67.78% |
| New Positions | 9 | New | 114,175 | New |
| Sold Out Positions | 3 | Sold Out | 684,257 | Sold Out |
| Total Postitions | 30 | +15.38% | 489,213 | -51.83% |
CLNN Ownership Change vs Market
Institutional Investor Ownership
| Vanguard Group Inc | $537.00 | 1.62% | 129,620 | -1,486 | -1.13% | 2024-12-31 |
| Scoggin Management Lp | $414.00 | 1.25% | 100,000 | +25,000 | +33.33% | 2024-12-31 |
| Geode Capital Management, Llc | $270.00 | 0.81% | 65,112 | +22,539 | +52.94% | 2024-12-31 |
| Parsons Capital Management Inc/Ri | $151.00 | 0.46% | 36,500 | +36,500 | New | 2024-12-31 |
| Lunt Capital Management, Inc. | $123.00 | 0.37% | 29,793 | +253 | +0.86% | 2024-12-31 |
| Citadel Advisors Llc | $86.00 | 0.26% | 20,835 | +20,835 | New | 2024-12-31 |
| Renaissance Technologies Llc | $75.00 | 0.23% | 18,040 | +18,040 | New | 2024-12-31 |
| Morgan Stanley | $70.00 | 0.21% | 16,931 | 0 | 0% | 2024-12-31 |
| Sbi Securities Co., Ltd. | $54.00 | 0.16% | 13,025 | +13,025 | New | 2024-12-31 |
| Fullcircle Wealth Llc | $54.00 | 0.16% | 13,023 | +13,023 | New | 2024-12-31 |